Physician profile
Adit Mahale
NPI 1144247750
$4,061.06
in general payments reported to CMS, 2019-2025
26 companies · $1,630 in 2025
The $1,630 reported for 2025 was more than what 87% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $311 · 2020: $16.62 · 2021: $119 · 2022: $527 · 2023: $503 · 2024: $955 · 2025: $1,630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,026 · Education: $60.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,026.46 |
| Education | $60.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $972.02 | 2024-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $408.49 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $265.67 | 2022-2023 | Ultomiris |
| Nxstage Medical, INC. | $197.38 | 2022-2024 | |
| Mallinckrodt Hospital Products INC. | $190.97 | 2020-2025 | Terlivaz |
| Outset Medical INC | $171.12 | 2023 | |
| Glaxosmithkline, LLC. | $160.13 | 2022-2023 | Benlysta |
| Apellis Pharmaceuticals, INC. | $151.93 | 2025 | Empaveli |
| Bayer Healthcare Pharmaceuticals INC. | $137.23 | 2024-2025 | |
| Amgen INC. | $134.22 | 2022-2025 | Tavneos |
| Aurinia Pharma U.S., INC. | $118.89 | 2021 | |
| Veloxis Pharmaceuticals, INC. | $118.78 | 2022-2025 | Envarsus |
| Cycle Pharmaceuticals INC | $100.94 | 2025 | Venxxiva |
| Otsuka America Pharmaceutical, INC. | $100.39 | 2019 | |
| Mallinckrodt Enterprises LLC | $99.99 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| One Lambda, INC. | $98.32 | 2025 | |
| Horizon Therapeutics Plc | $91.40 | 2023 | Krystexxa |
| Janssen Pharmaceuticals, INC | $89.13 | 2019 | |
| Solventum Corporation | $80.00 | 2025 | V.A.C. Veraflo, V.A.C.Ulta, Prevena |
| Kci USA, INC. | $76.80 | 2023 | Prevena, V.A.C. Veraflo |
| Cormedix INC. | $73.57 | 2025 | Defencath |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.25 | 2024-2025 | Jardiance |
| Novo Nordisk INC | $63.21 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Akebia Therapeutics INC | $48.53 | 2024-2025 | Vafseo |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.81 | 2019 | |
| Travere Therapeutics, INC. | $16.89 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adit Mahale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.